Regulation of Self-Care Products in Canada
https://policybase.cma.ca/link/policy13802

POLICY TYPE  Response to consultation
DATE  2016-10-31
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE: Parliamentary submission
DATE: 2016-10-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE
Response to consultation

DATE
2016-08-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana Legalization and Regulation

August 29, 2016

STANDARD DÉCLARATION

Choi statement - Application d’Herbert

Health, September 11, 2016 - The CMA’s submission to the Task Force on Marijuana Legalization and Regulation is intended to reiterate the importance of patient-centred care and to stress the need for a comprehensive approach to the legal, health, and social issues associated with the regulation of marijuana.

The CMA has long been an advocate of plain and standardized packaging of prescription medications. This initiative is designed to improve the safety and health of patients by reducing the risk of medication errors and adverse drug events.

As such, the CMA’s submission is intended to complement the recommendations of the Task Force by highlighting the importance of a holistic approach to the regulation of marijuana. The CMA’s recommendations focus on the need for a clear and comprehensive approach to the regulation of marijuana, including the implementation of plain and standardized packaging.

The CMA recommends that the Task Force consider the following points:

1. The CMA recommends that the Task Force consider the importance of plain and standardized packaging of prescription medications, as it can improve patient safety and health outcomes.

2. The CMA recommends that the Task Force consider the importance of a comprehensive approach to the regulation of marijuana, including the implementation of plain and standardized packaging.

3. The CMA recommends that the Task Force consider the importance of ensuring that the implementation of plain and standardized packaging is consistent with the best available evidence.

For information, please contact:

Herbert Choi, MD
Canadian Medical Association

NOTE: The CMA’s submission to the Task Force on Marijuana Legalization and Regulation is available online at www.cma.ca.
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE
Response to consultation

DATE
2016-08-12

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
National pharmacare in Canada: Getting there from here
https://policybase.cma.ca/link/policy11959

POLICY TYPE  Parliamentary submission
DATE  2016-06-01
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE
Response to consultation

DATE
2016-03-19

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

POLICY TYPE  Response to consultation
DATE  2016-01-20
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
  Health care and patient safety

Documents